强化家庭血液透析生存率与尸体供肾移植相当
调整分析显示IHHD患者生存率与尸体供肾移植受者无统计学差异(HR 0.96;95%CI 0.62-1.48),但低于活体供肾移植受者(HR 0.53;95%CI 0.34-0.83)。结论认为对合适患者,IHHD可作为移植桥接或长期肾脏替代治疗。
要点
- IHHD与尸体供肾移植全因死亡风险无显著差异(HR 0.96;95%CI 0.62-1.48)。
- 活体供肾移植生存率最高,较IHHD死亡风险降低47%(HR 0.53;95%CI 0.34-0.83)。
- IHHD与边缘供肾移植(KDPI>85%)生存率亦无统计学差异(HR 1.35;95%CI 0.84-2.16)。
核心结论
- IHHD与尸体供肾移植总体生存率相当,可作为合适患者的桥接治疗或长期肾脏替代治疗。
主要发现
- 活体供肾移植(n=1212)生存率最高,较IHHD死亡风险降低47%(HR 0.53;95%CI 0.34-0.83)。
- IHHD与尸体供肾移植(n=1834)调整后死亡风险无统计学差异(HR 0.96;95%CI 0.62-1.48)。
- IHHD与边缘供肾移植(KDPI>85%)比较死亡风险无统计学差异(HR 1.35;95%CI 0.84-2.16)。
临床怎么用
- 对无法及时获得移植的终末期肾病患者,IHHD可作为桥接移植或长期替代治疗选择。
- 临床决策时需结合患者意愿、家庭条件及移植可及性综合评估IHHD适用性。
局限性
- 回顾性设计,IHHD数据仅来自单一经验丰富的美国项目,样本量较小(116例),外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Kidney transplantation (KT) remains the treatment of choice for end-stage kidney disease (ESKD), but access to transplantation is limited by a disparity between supply and demand for suitable organs. This organ shortfall has resulted in the use of a wider range of donor kidneys and, in parallel, a reexamination of potential alternative renal replacement therapies. Previous studies comparing Canadian intensive home hemodialysis (IHHD) with deceased donor (DD) KT in the United States reported similar survival, suggesting IHHD might be a plausible alternative. METHODS: Using data from the Scientific Registry of Transplant Recipients and an experienced US-based IHHD program in Lynchburg, VA, we retrospectively compared mortality outcomes of a cohort of IHHD patients with transplant recipients within the same geographic region between October 1997 and June 2014. RESULTS: We identified 3073 transplant recipients and 116 IHHD patients. Living donor KT (n = 1212) had the highest survival and 47% reduction in risk of death compared with IHHD (hazard ratio [HR]: 0.53; 95% confidence interval [CI]: 0.34-0.83). Survival of IHHD patients did not statistically differ from that of DD transplant recipients (n = 1834) in adjusted analyses (HR: 0.96; 95% CI: 0.62-1.48) or when exclusively compared with marginal (Kidney Donor Profile Index >85%) transplant recipients (HR: 1.35; 95% CI: 0.84-2.16). CONCLUSION: Our study showed comparable overall survival between IHHD and DD KT. For appropriate patients, IHHD could serve as bridging therapy to transplant and a tenable long-term renal replacement therapy.
引用
- Nishio-Lucar AG, Bose S, Lyons G, et al. Intensive Home Hemodialysis Survival Comparable to Deceased Donor Kidney Transplantation. Kidney Int Rep. 2020. PMID: 32154451. doi:10.1016/j.ekir.2019.12.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。